SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)
[Item 5.07. ach of the seven (7) director-nominees: Name of Nominee Votes For]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: Item 5.07. ach of the seven (7) director-nominees:
[Item 5.07. ach of the seven (7) director-nominees: Name of Nominee Votes For]
GURE [GULF RESOURCES] 8-K: (Original Filing)
[Crude Salt Field Acquisition Agreement Transferor: State Operated Shouguang Qingshuibo Farm (Hereinafter referred to as Party A) Registered Address: Yangkou Township, Shouguang City, Shandong Province, PRC Legal Representative: Changjun Li Business Registration Number: N/A Transferee: Shouguang City Haoyuan Chemical Co., Ltd. (hereinafter referred to as Party B) Registered Address: The South Side of Bamian Village, Wopu Township, Shouguang City, Shandong] [EX-10.2 3 e607910_ex10-2.htm] [Contact: Gulf Resources, Inc. David Wang, VP of Finance Email: gfre.2008@vip.163.com Helen Xu Email: beishengrong@vip.163.com http://www.gulfresourcesinc.cn Web: CCG Investor Relations Inc. Linda Salo, Sr. Financial Writer Phone: +1-646-922-0894 Email: linda.salo@ccgir.com Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: crocker.coulson@ccgir.com http://www.ccgirasia.com Web: Gulf Resources Agrees to Acquire Crude Salt Field NEW YORK and SHANDONG, China, January 4, 2011 -- Gulf Resources,] [+86 (536) 567 0008 o o o o Item 1.01 Entry into a Material Definitive Agreement. On December 30, 2010, Shouguang City Haoyuan Chemical Co., Ltd. ("SCHC"), a wholly-owned subsidiary of Gulf Resources, Inc. (the “Company”), entered into a Crude Salt Field Acquisition Agreement (the “Agreement”) with State-Operated Shouguang Qingshuibo Farm (the “Transferor”). an annual leasing fee of RMB172,500 (approximately]
GURE [GULF RESOURCES] 8-K: Crude Salt Field Acquisition Agreement Transferor: State Operated
[Crude Salt Field Acquisition Agreement Transferor: State Operated Shouguang Qingshuibo Farm (Hereinafter referred to as Party A) Registered Address: Yangkou Township, Shouguang City, Shandong Province, PRC Legal Representative: Changjun Li Business Registration Number: N/A Transferee: Shouguang City Haoyuan Chemical Co., Ltd. (hereinafter referred to as Party B) Registered Address: The South Side of Bamian Village, Wopu Township, Shouguang City, Shandong] [EX-10.2 3 e607910_ex10-2.htm] [Contact: Gulf Resources, Inc. David Wang, VP of Finance Email: gfre.2008@vip.163.com Helen Xu Email: beishengrong@vip.163.com http://www.gulfresourcesinc.cn Web: CCG Investor Relations Inc. Linda Salo, Sr. Financial Writer Phone: +1-646-922-0894 Email: linda.salo@ccgir.com Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: crocker.coulson@ccgir.com http://www.ccgirasia.com Web: Gulf Resources Agrees to Acquire Crude Salt Field NEW YORK and SHANDONG, China, January 4, 2011 -- Gulf Resources,] [+86 (536) 567 0008 o o o o Item 1.01 Entry into a Material Definitive Agreement. On December 30, 2010, Shouguang City Haoyuan Chemical Co., Ltd. ("SCHC"), a wholly-owned subsidiary of Gulf Resources, Inc. (the “Company”), entered into a Crude Salt Field Acquisition Agreement (the “Agreement”) with State-Operated Shouguang Qingshuibo Farm (the “Transferor”). an annual leasing fee of RMB172,500 (approximately]
CCCL [China Ceramics] 6-K: (Original Filing)
[Copy of correspondence to: Stuart Management Company 33 Riverside Avenue th 5 Westport, CT 06880 x ¨ Form 20-F ¨ ¨ ¨ x Yes EXPLANATORY NOTE 2 CHINA CERAMICS CO., LTD. AND ITS SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (RMB in thousands, except EPS and share data) Six months ended June 30,]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Receives SFDA Approval to Commence Clinical Trials For Inactivated Enterovirus Type 71 Vaccine BEIJING, December 28, 2010 /PRNewswire-Asia/ Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it received approval from the China State Food and Drug Administration (SFDA) to commence clinical trials for its proprietary inactivated EV71 vaccine against Hand,] [BEIJING, December 31, 2010 /PRNewswire-Asia/ Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its common shares will be listed on the NASDAQ Global Select Market effective January 3, 2011. The Company received notification from the NASDAQ Stock Market dated December 7, 2010 that as part of the exchanges annual review of Global] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Receives SFDA Approval to Commence Clinical Trials
[Sinovac Receives SFDA Approval to Commence Clinical Trials For Inactivated Enterovirus Type 71 Vaccine BEIJING, December 28, 2010 /PRNewswire-Asia/ Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it received approval from the China State Food and Drug Administration (SFDA) to commence clinical trials for its proprietary inactivated EV71 vaccine against Hand,] [BEIJING, December 31, 2010 /PRNewswire-Asia/ Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its common shares will be listed on the NASDAQ Global Select Market effective January 3, 2011. The Company received notification from the NASDAQ Stock Market dated December 7, 2010 that as part of the exchanges annual review of Global] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]
CTC [IFM Investments] 6-K: (Original Filing)
[This Form 6-K consists of: on the regional business updates An announcement]
